RANDOMIZED, OPEN LABEL, ACTIVE CONTROLLED STUDY TO ASSESS AND COMPARE HEALTH RELATED QUALITY OF LIFE WITH MOMETASONE & FORMOTEROL VERSUS FLUTICASONE & FORMOTEROL DRY POWDER INHALER IN MILD TO MODERATE PERSISTENT ASTHMA
Objectives: The present study was under taken to assess and compare the improvement in HRQoL among mild to moderate persistent asthma
between Mometasone & Formoterol versus Fluticasone & Formoterol using dry powder inhaler using Asthma HRQoL questionnaire which is diseasespecific
32-item instrument including 4 domains: symptoms, emotions, exposure to environmental stimuli and activity limitations where impairments
experienced during the previous 14 days and respond on 7-point scale.
Methods: The present study was conducted in Preventive Medicine Unit and Chest & TB diseases OPD, KIMS & RC, Bangalore during March 2011 to
February 2012. 60 patients were recruited in each group based on inclusion and exclusion criteria. PFT was done pre and post bronchodilator with
Salbutamol nebulization with Spirometry. Study medications were randomized and were given for 12weeks. HRQoL questionnaire was administered
before and after the medications and outcome was compared between them. Statistical test used were descriptive statistics, t- test.
Results: There was a significant improvement in HRQoL from baseline to the end of 12 weeks in all domains (symptoms, emotional, exposure to
environmental stimuli and activity limitations) in both the groups. The overall improvement in the HRQoL was better in Mometasone & Formoterol
group compared to Fluticasone & Formoterol group but this difference was not statistically significant, which revealed both combinations were
equally effective in improving HRQoL in mild to moderate persistent asthma.
Conclusion: Both Mometasone & Formoterol and Fluticasone & Formoterol combinations are equally effective in improving HRQoL in mild to
moderate persistent asthma patients.
Keywords: Health-related quality of life, Mild to moderate persistent asthma, Dry powder inhaler.
1. Masoli M, Fabian D, Holt S, Beasley R, Global Initiative for Asthma (GINA) Program. The global burden of asthma: Executive summary of the GINA Dissemination Committee report. Allergy 2004;59(5):469-78.
2. Barnes PJ. Scientific rationale for inhaled combination therapy with long-acting Î²2- agonists and corticosteroids. Eur Respir J 2002;19:182-91.
3. Dâ€™Urzo A. Mometasone furoate dry-powder inhaler for the control of persistent asthma. Expert Opin Pharmacother 2007;8(16):2871-84.
4. Voll-Aanerud M, Eagan TM, Plana E, Omenaas ER, Bakke PS, Svanes C, et al. Respiratory symptoms in adults are related to impaired quality of life, regardless of asthma and COPD: Results from the European community respiratory health survey. Health Qual Life Outcomes 2010;8:107.
5. Juniper EF, Guyatt GH, Epstein RS, Ferrie PJ, Jaeschke R, Hiller TK. Evaluation of impairment of health related quality of life in asthma: Development of a questionnaire for use in clinical trials. Thorax 1992;47(2):76-83.
6. Wardlaw A, Larivee P, Eller J, Cockcroft DW, Ghaly L, Harris AG. Efficacy and safety of mometasone furoate dry powder inhaler vs. fluticasone propionate metered-dose inhaler in asthma subjects previously using fluticasone propionate. Ann Allergy Asthma Immunol 2004;93(1):49-55.
7. Kumar N, Gupta N, Kishore J. Kuppuswamyâ€™s socioeconomic scale: updating income ranges for the year 2012. Indian J Public Health 2012;56(1):103-4.
8. Bernstein DI, Hebert J, Cheema A, Murphy KR, Cheerez-Ojeda I, Matiz-Bueno CE, et al. Efficacy and onset of action of mometasone furoate/formoterol and fluticasone propionate/salmeterol combination treatment in subjects with persistent asthma. Allergy Asthma Clin Immunol 2011;7:21.
The publication is licensed under CC By and is open access. Copyright is with author and allowed to retain publishing rights without restrictions.